- Business Wire•yesterdayU.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application for Opdivo (nivolumab) in Previously Treated Patients With Advanced Form of Bladder Cancer
Bristol-Myers Squibb Company announced today that the U.S. Food and Drug Administration accepted a supplemental Biologics License Application , which seeks to expand the use of Opdivo to patients with locally advanced unresectable or metastatic urothelial carcinoma that has progressed on or after platinum-containing therapy.
- Benzinga•2 days ago
When it comes to big pharmaceutical companies, there look to be few things more alluring than new treatments for cancer, according to analysts who follow drug tests closely. Tuesday’s lineup of earnings ...
- Business Wire•2 days agoBristol-Myers Squibb Updates Conference Call Dial-in/ID for Third Quarter 2016 Results on October 27
Bristol-Myers Squibb Company will announce results for the third quarter of 2016 on Thursday, October 27, 2016. During a conference call at 10:30 a.m. EDT on October 27, company executives will review financial information and will address inquiries from investors and analysts.
Bristol-Myers Squibb Company (BMY)
NYSE - NYSE Real Time Price. Currency in USD
|Bid||49.91 x 300|
|Ask||50.00 x 100|
|Day's Range||49.88 - 50.45|
|52wk Range||49.10 - 77.12|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||29.25|
|Avg Vol (3m)||14,116,973|
|Dividend & Yield||1.52 (3.08%)|